Monitor for interim data or updates from the Phase 1b/2a trial in late 2026; while this is an early-stage catalyst, success could revalue the pipeline, especially given the large target market. However, no revenue or earnings contribution is expected for several years.
Price Chart
Executive Summary
Pelthos Therapeutics announced the first patient dosed in a Phase 1b/2a trial for CT2000, a novel eye drop targeting NaV1.7 for chronic ocular pain associated with dry eye disease. The trial results are expected by end of 2026, representing an early but meaningful step in advancing its preclinical-stage pipeline. This is a developmental milestone with no immediate financial impact.
Key Facts
- First patient dosed in Phase 1b/2a clinical trial evaluating CT2000 for acute and chronic ocular pain due to dry eye disease.
- Trial is placebo-controlled, adaptive design, with safety and efficacy endpoints; results expected by end of 2026.
- CT2000 is a topical NaV1.7 inhibitor, a target implicated in peripheral pain signaling, with preclinical success in animal models announced in May 2025.
- The global chronic ocular pain market is projected to reach $5.3 billion by 2032.
- CT2000 is part of Channel Therapeutics, a subsidiary of Pelthos, and is being developed through its Australian arm.
Financial Impact
No immediate financial impact; potential long-term value if clinical development succeeds.
Risk Factors
- High risk of clinical trial failure, especially in early-phase development.
- No guarantee of efficacy in humans despite positive preclinical results.
- Dilution risk if future funding is required to advance CT2000.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers